Corneal scar. Corneal scars and opacities
Conditions
Interventions
Intervention group: A 0.8 mg/mL sterile ophthalmic solution of losartan (manufactured by Loghman Pharmaceutical Company, Iran) prepared in balanced salt solution and sterilized using a 0.22 µm filter
Sponsors
Semnan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Post-LASEK Herpes simplex keratitis Corneal scar after any ophthalmic surgery
Exclusion criteria
Exclusion criteria: Presence of systemic diseases such as cancer or diabetes. History of using diuretic medications. Pregnant or breastfeeding individuals. History of using non-steroidal anti-inflammatory drugs (NSAIDs). Individuals with renal (kidney) disorders. Active ocular infection. Severe ocular inflammation. Occurrence of any complications during the study, including decreased visual acuity, drug hypersensitivity, or patient dissatisfaction with continued participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best corrected visual acuity. Timepoint: Pre-treatment, 1-week, 1-month, 3-month post-treatment. Method of measurement: Using E-chart and lenses.;Intraocular pressure (IOP). Timepoint: Pre-treatment, 1-week, 1-month, 3-month post-treatment. Method of measurement: I-care tonometer.;Scar depth. Timepoint: Pre-treatment, 1-week, 1-month, 3-month post-treatment. Method of measurement: Anterior-segment optical coherence tomography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactKhosrow Jadidi
Vision Health Research Center
Outcome results
None listed